DEEP EXPERIENCE. SHARED COMMITMENT.
"We take a private equity approach to a sector that’s traditionally been dominated by venture and early-stage growth firms. We'll work very closely with management to improve the operations of the business, update the product portfolio and revamp the commercial organization. We provide the support and resources our portfolio companies need to succeed.”
19
active portfolio companies
+
2000
employees worldwide
5
AP-II Investments to Date
9
successful exits
news
Aug 08, 2022
Accelmed Partners II (AP-II) Q2 2022 Update
While focusing on securing liquidity for our portfolio companies and taking measures to contain costs, we continue to seek new investments and are glad to report a new member of the Accelmed portfolio, Veranex.
May 19, 2022
Veranex Announces Strategic Investments From Accelmed Partners and Lauxera Capital PartnersVeranex — the only global, tech-enabled product development services provider focused on the medical technology industry — today announced strategic partnerships with Accelmed Partners II and Lauxera Capital Partners.
Oct 22, 2021
Accelmed and H.I.G. BioHealth Co-Lead $52 Million Series B for Click TherapeuticsClick Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has closed a $52 million upsized Series B financing
Sep 01, 2021
Keystone Dental acquires Osteon Medical, raises $25m led by NantahalaAccelmed Partners I portfolio company Keystone Dental Inc. announced the acquisition of Osteon Medical and the completion of a $25 million financing round led by Nantahala, with participation from Accelmed and Migdal Insurance.
Contact Us